Why the racing industry and equestrian disciplines need to implement population pharmacokinetics: To learn, explain, summarize, harmonize, and individualize
Population pharmacokinetics (POP PK) is a powerful pharmacokinetic tool, which measures quantitatively, and explains the variability in drug exposure and drug effect between individuals. POP PK uses an observational (nonexperimental) approach; it is conducted in the target population living in its n...
Saved in:
Published in | Drug testing and analysis Vol. 17; no. 2; pp. 250 - 258 |
---|---|
Main Author | |
Format | Journal Article |
Language | English |
Published |
England
01.02.2025
|
Subjects | |
Online Access | Get full text |
ISSN | 1942-7603 1942-7611 |
DOI | 10.1002/dta.3706 |
Cover
Loading…
Abstract | Population pharmacokinetics (POP PK) is a powerful pharmacokinetic tool, which measures quantitatively, and explains the variability in drug exposure and drug effect between individuals. POP PK uses an observational (nonexperimental) approach; it is conducted in the target population living in its normal environment (e.g., farm and race‐track). The strength of the POP PK approach lies in its greater relevance for the population studied in its different natural environments than experimental studies carried out in more or less biased laboratory conditions. In clinical settings, it is commonly necessary to restrict the number of samples per subject collected for analysis and the derived data cannot be analyzed using traditional individual data analytical methods; rather data are merged and analyzed with an appropriate statistical tool: the nonlinear mixed effect model (NLMEM). POP PK modeling is frequently used with the objective of adjusting drug dosage, and hence drug exposure, not only for the whole population but also for subgroups of animals (e.g., for a given breed, sex, and age). It can also have application at the individual subject level, in the context of precision medicine. For horses, the use of the POP PK/PD model will allow prescribers to estimate an individual Withdrawal Time for a given horse whose treatment they are supervising. Another potential field of application will be meta‐analysis of existing data to generate new knowledge on a drug or to collate and synthesize, in an objective and transparent manner, existing data; this will facilitate harmonization of screening limits at an international level.
Population pharmacokinetics (POP PK) is a pharmacokinetic tool, which measures and explains the variability in drug exposure and drug effect between individuals. For prescribers, POP PK model will allow to estimate an individual Withdrawal Time for a given horse. For scientists, POP PK model will allow meta‐analysis of existing data and to generate new drug knowledge. For organisations, POP PK model will allow to objectively and impartially summarize the data available to experts, facilitating consensus when establishing international screening limits. |
---|---|
AbstractList | Population pharmacokinetics (POP PK) is a powerful pharmacokinetic tool, which measures quantitatively, and explains the variability in drug exposure and drug effect between individuals. POP PK uses an observational (nonexperimental) approach; it is conducted in the target population living in its normal environment (e.g., farm and race‐track). The strength of the POP PK approach lies in its greater relevance for the population studied in its different natural environments than experimental studies carried out in more or less biased laboratory conditions. In clinical settings, it is commonly necessary to restrict the number of samples per subject collected for analysis and the derived data cannot be analyzed using traditional individual data analytical methods; rather data are merged and analyzed with an appropriate statistical tool: the nonlinear mixed effect model (NLMEM). POP PK modeling is frequently used with the objective of adjusting drug dosage, and hence drug exposure, not only for the whole population but also for subgroups of animals (e.g., for a given breed, sex, and age). It can also have application at the individual subject level, in the context of precision medicine. For horses, the use of the POP PK/PD model will allow prescribers to estimate an individual Withdrawal Time for a given horse whose treatment they are supervising. Another potential field of application will be meta‐analysis of existing data to generate new knowledge on a drug or to collate and synthesize, in an objective and transparent manner, existing data; this will facilitate harmonization of screening limits at an international level.
Population pharmacokinetics (POP PK) is a pharmacokinetic tool, which measures and explains the variability in drug exposure and drug effect between individuals. For prescribers, POP PK model will allow to estimate an individual Withdrawal Time for a given horse. For scientists, POP PK model will allow meta‐analysis of existing data and to generate new drug knowledge. For organisations, POP PK model will allow to objectively and impartially summarize the data available to experts, facilitating consensus when establishing international screening limits. Population pharmacokinetics (POP PK) is a powerful pharmacokinetic tool, which measures quantitatively, and explains the variability in drug exposure and drug effect between individuals. POP PK uses an observational (nonexperimental) approach; it is conducted in the target population living in its normal environment (e.g., farm and race-track). The strength of the POP PK approach lies in its greater relevance for the population studied in its different natural environments than experimental studies carried out in more or less biased laboratory conditions. In clinical settings, it is commonly necessary to restrict the number of samples per subject collected for analysis and the derived data cannot be analyzed using traditional individual data analytical methods; rather data are merged and analyzed with an appropriate statistical tool: the nonlinear mixed effect model (NLMEM). POP PK modeling is frequently used with the objective of adjusting drug dosage, and hence drug exposure, not only for the whole population but also for subgroups of animals (e.g., for a given breed, sex, and age). It can also have application at the individual subject level, in the context of precision medicine. For horses, the use of the POP PK/PD model will allow prescribers to estimate an individual Withdrawal Time for a given horse whose treatment they are supervising. Another potential field of application will be meta-analysis of existing data to generate new knowledge on a drug or to collate and synthesize, in an objective and transparent manner, existing data; this will facilitate harmonization of screening limits at an international level. |
Author | Toutain, Pierre‐Louis |
Author_xml | – sequence: 1 givenname: Pierre‐Louis orcidid: 0000-0002-8846-8892 surname: Toutain fullname: Toutain, Pierre‐Louis email: pltoutain@wanadoo.fr organization: University of London |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38685692$$D View this record in MEDLINE/PubMed |
BookMark | eNo9kE1OwzAQhS1URGlB4gTIB2iKHSdOza4qv1IlNkUsI8eZUEPimDgBwlk4LA6FrubNzKd5ozdBI1MbQOiMkjklJLzIWzlnCeEH6JiKKAwSTulorwkbo4lzL4TwKGTxERqzBV_EXITH6Ptp2-N2C7iRSptnrE3eubbpsTQ5hrcOfKOlwbl2SttSG3DYAOS4rbGubAkVmBbb2nalbHVtsN3KppKqfvVoq5W7xJsalyAbM8PwaUupvXBdVclGf8EMD3htfuVg6f31u847WfrRCTosZOng9K9O0ePN9WZ1F6wfbu9Xy3WgooTxQAkOjKhMLiIBRaZEpApGiCpU4ecxp5EUgnIZZzSkGZCwWMgkCZUSWcwzz07R-e6u7bIK8tQ22r_Xp_8xeSDYAR-6hH6_pyQd4k99_OkQf3q1WQ6V_QCTSn3Q |
CitedBy_id | crossref_primary_10_1002_dta_3882 crossref_primary_10_1111_jvp_13491 crossref_primary_10_3389_fvets_2024_1454342 |
ContentType | Journal Article |
Copyright | 2024 The Author. published by John Wiley & Sons Ltd. 2024 The Author. Drug Testing and Analysis published by John Wiley & Sons Ltd. |
Copyright_xml | – notice: 2024 The Author. published by John Wiley & Sons Ltd. – notice: 2024 The Author. Drug Testing and Analysis published by John Wiley & Sons Ltd. |
DBID | 24P CGR CUY CVF ECM EIF NPM |
DOI | 10.1002/dta.3706 |
DatabaseName | Wiley Online Library Open Access Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: 24P name: Wiley Online Library Open Access (Activated by CARLI) url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1942-7611 |
EndPage | 258 |
ExternalDocumentID | 38685692 DTA3706 |
Genre | reviewArticle Journal Article Review |
GroupedDBID | --- 05W 0R~ 1OC 24P 31~ 33P 4.4 53G 5DZ 5GY 8-0 8-1 A00 AAESR AAHHS AAHQN AAMNL AANHP AANLZ AAYCA AAZKR ABCUV ABJNI ACBWZ ACCFJ ACCZN ACGFS ACPOU ACRPL ACXQS ACYXJ ADBBV ADKYN ADNMO ADXAS ADZMN ADZOD AEEZP AEIGN AENEX AEQDE AEUYR AFBPY AFFPM AFWVQ AHBTC AHMBA AITYG AIURR AIWBW AJBDE ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMYDB ASPBG AVWKF AZFZN AZVAB BDRZF BFHJK BMXJE BRXPI DCZOG DU5 EBD EBS EJD EMOBN F5P FEDTE G-S GODZA HGLYW HVGLF HZ~ LATKE LEEKS LH4 LITHE LOXES LUTES LW6 LYRES MEWTI MK0 MY. MY~ NNB O9- OIG P2P P2W P4E PQQKQ ROL SUPJJ SV3 TUS WBKPD WOHZO WXSBR WYJ XV2 ZZTAW AAMMB AEFGJ AEYWJ AGHNM AGQPQ AGXDD AGYGG AIDQK AIDYY CGR CUY CVF ECM EIF NPM |
ID | FETCH-LOGICAL-c4736-c96e30cba849efbc94cf300cfcfe305614a9916a5b121be02f8a772cc9b56bcf3 |
IEDL.DBID | 24P |
ISSN | 1942-7603 |
IngestDate | Mon Jul 21 05:57:09 EDT 2025 Fri Feb 21 09:20:12 EST 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Keywords | medication control nonlinear mixed effect model withdrawal time horses population pharmacokinetics |
Language | English |
License | Attribution 2024 The Author. Drug Testing and Analysis published by John Wiley & Sons Ltd. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c4736-c96e30cba849efbc94cf300cfcfe305614a9916a5b121be02f8a772cc9b56bcf3 |
ORCID | 0000-0002-8846-8892 |
OpenAccessLink | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fdta.3706 |
PMID | 38685692 |
PageCount | 9 |
ParticipantIDs | pubmed_primary_38685692 wiley_primary_10_1002_dta_3706_DTA3706 |
PublicationCentury | 2000 |
PublicationDate | February 2025 |
PublicationDateYYYYMMDD | 2025-02-01 |
PublicationDate_xml | – month: 02 year: 2025 text: February 2025 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | Drug testing and analysis |
PublicationTitleAlternate | Drug Test Anal |
PublicationYear | 2025 |
References | 1997; 61 2023; 14 2013; 2 2023; 12 2015; 104 2011 1991; 32 2004; 27 2010 1982; 50 2018; 41 1985; 85 2020; 11 2003 1972; 5 1998; 21 2017; 50 2010; 42 2013; 36 2021; 53 2012; 1 2021; 11 2022; 14 2022; 54 2013; 198 2022; 11 |
References_xml | – year: 2011 – start-page: 19 year: 2003 end-page: 27 – volume: 27 start-page: 427 issue: 6 year: 2004 end-page: 439 article-title: Plasma terminal half‐life publication-title: J Vet Pharmacol Ther – volume: 85 start-page: 1002 year: 1985 end-page: 1009 article-title: In defense of probability publication-title: Proc Ninth Int Joint Conf Artif Intell – volume: 61 start-page: 275 issue: 3 year: 1997 end-page: 291 article-title: Learning versus confirming in clinical drug development publication-title: Clin Pharmacol Ther – volume: 11 year: 2021 article-title: Personalized medicine of monoclonal antibodies in inflammatory bowel disease: pharmacogenetics, therapeutic drug monitoring, and beyond publication-title: Front Pharmacol – volume: 11 start-page: 469 issue: 4 year: 2022 end-page: 481 article-title: Model‐based meta‐analysis of salbutamol pharmacokinetics and practical implications for doping control publication-title: CPT Pharm Syst Pharma – volume: 50 start-page: 488 issue: 4 year: 2017 end-page: 492 article-title: Pharmacokinetics of tiludronate in horses: a field population study publication-title: Equine Vet J – volume: 104 start-page: 1230 issue: 4 year: 2015 end-page: 1239 article-title: A framework for meta‐analysis of veterinary drug pharmacokinetic data using mixed effect modeling publication-title: J Pharm Sci – volume: 36 start-page: 31 issue: 1 year: 2013 end-page: 42 article-title: A Bayesian approach for estimating detection times in horses: exploring the pharmacokinetics of a urinary acepromazine metabolite publication-title: J Vet Pharmacol Ther – volume: 50 start-page: 1 issue: 1 year: 1982 end-page: 11 article-title: Scoring rules and the inevitability of probability publication-title: Int Stat Rev Revue Int de Stat – volume: 1 start-page: 9 issue: 6 year: 2012 end-page: 14 article-title: Basic concepts in population modeling, simulation, and model‐based drug development publication-title: CPT: Pharmacomet Syst Pharmacol – volume: 12 start-page: 883 issue: 7 year: 2023 end-page: 888 article-title: Requirements, expectations, challenges and opportunities associated with training the next generation of pharmacometricians publication-title: CPT Pharmacom Syst Pharma – volume: 27 start-page: 467 issue: 6 year: 2004 end-page: 477 article-title: Integration and modelling of pharmacokinetic and pharmacodynamic data to optimize dosage regimens in veterinary medicine publication-title: J Vet Pharmacol Ther – volume: 11 year: 2020 article-title: Precision dosing priority criteria: drug, disease, and patient population variables publication-title: Front Pharmacol – volume: 5 start-page: 411 issue: 5 year: 1972 end-page: 459 article-title: Modelling of individual pharmacokinetics for computer‐aided drug dosage publication-title: Comput Biomed Res – start-page: 315 year: 2010 end-page: 339 article-title: Veterinary medicines and competition animals: the question of medication versus doping control publication-title: Handb Exp Pharmacol – volume: 14 issue: 2 year: 2022 article-title: Free and open‐source Posologyr software for Bayesian dose individualization: an extensive validation on simulated data publication-title: Pharmaceutics – volume: 42 start-page: 248 issue: 3 year: 2010 end-page: 254 article-title: How to extrapolate a withdrawal time from an EHSLC published detection time: a Monte Carlo simulation appraisal: doping control and withdrawal time publication-title: Equine Vet J – volume: 198 start-page: 313 issue: 2 year: 2013 end-page: 321 article-title: A clinician's guide to factors affecting withdrawal times for equine therapeutic medications publication-title: Vet J – volume: 14 year: 2023 article-title: Pharmacokinetic–pharmacodynamic cutoff values for benzylpenicillin in horses to support the establishment of clinical breakpoints for benzylpenicillin antimicrobial susceptibility testing in horses publication-title: Front Microbiol – volume: 32 start-page: 669 issue: 6 year: 1991 end-page: 670 article-title: Population pharmacokinetics: theory and practice publication-title: Br J Clin Pharmacol – volume: 41 start-page: 171 issue: 2 year: 2018 end-page: 183 article-title: Mathematical modeling and simulation in animal health. Part III: using nonlinear mixed‐effects to characterize and quantify variability in drug pharmacokinetics publication-title: J Vet Pharmacol Ther – volume: 54 start-page: 979 issue: 5 year: 2022 end-page: 988 article-title: Medication control of flunixin in racing horses: possible detection times using Monte Carlo simulations publication-title: Equine Vet J – volume: 12 start-page: 1187 issue: 9 year: 2023 end-page: 1200 article-title: Pharmacokinetic analysis across studies to drive knowledge‐integration: a tutorial on individual patient data meta‐analysis (IPDMA) publication-title: CPT Pharmacom Syst Pharma – volume: 21 start-page: 167 issue: 3 year: 1998 end-page: 189 article-title: Population pharmacokinetics in veterinary medicine: potential use for therapeutic drug monitoring and prediction of tissue residues publication-title: J Vet Pharmacol Ther – volume: 2 year: 2013 article-title: Basic concepts in population modeling, simulation, and model‐based drug development‐part 2: introduction to pharmacokinetic modeling methods publication-title: CPT: Pharmacom Syst Pharmacol – volume: 27 start-page: 415 issue: 6 year: 2004 end-page: 425 article-title: Plasma clearance publication-title: J Vet Pharmacol Ther – volume: 53 start-page: 1047 issue: 5 year: 2021 end-page: 1055 article-title: Determination of the pharmacokinetic‐pharmacodynamic cut‐off values of marbofloxacin in horses to support the establishment of a clinical breakpoint for antimicrobial susceptibility testing publication-title: Equine Vet J |
SSID | ssj0064235 |
Score | 2.3958075 |
SecondaryResourceType | review_article |
Snippet | Population pharmacokinetics (POP PK) is a powerful pharmacokinetic tool, which measures quantitatively, and explains the variability in drug exposure and drug... |
SourceID | pubmed wiley |
SourceType | Index Database Publisher |
StartPage | 250 |
SubjectTerms | Animals horses Horses - metabolism medication control Models, Biological Nonlinear Dynamics nonlinear mixed effect model Pharmacokinetics population pharmacokinetics Precision Medicine - methods withdrawal time |
Title | Why the racing industry and equestrian disciplines need to implement population pharmacokinetics: To learn, explain, summarize, harmonize, and individualize |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fdta.3706 https://www.ncbi.nlm.nih.gov/pubmed/38685692 |
Volume | 17 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV09T8MwELVQWVgQ35Qv3YA6NZA6jpuwVUCFkEAdimCLbNcWEZBWbZEov4Ufy52TpowsSZRcYiln3z0nfu8YO3eGZhE8CjDXuUC4VAfaaBNEln7DCExgnPjOD4_y7kncv8Qv1apK4sKU-hD1BzcaGT5e0wBXena5Eg0dzdVF1CW17XVi1lLZBi4GyyiMsNoX18Q5OiJIGUZL4dmQXy7v_JN0_gJTn1n6W2yzgoTQK324zdZsscNag1JTetGG4YoiNWtDCwYrtenFLvt5fl0AojiYKoNpCPKyFscCVDEC66M-9rECavqtnUGBKQvmY8g_qtXjMKnreMGkevwbmlKTVzAcgy8u0Qb7NXlXOR6UnLf827aBzDEw0CE1mdcMLzy1x576t8Pru6AquRAY0Y1kYFJpo9BolYjUOm1SYVwUhsYZZ_1kQygClCrWHd7RNuQuUYjPjUl1LDXa7rNGMS7sIYNON9EmjrXmI_RBaJLEydAh_kHEJ0ZcNtlB-fazSamrkUWJTGKZ8iZreXfUF0ppZZ6h4zJyXHYz7NH-6L-Gx2yDU91ev9r6hDXm0097imBirs98r8Ht4-DhF463yrw |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV07T8MwELZQGWBBvCnPG1CnhqaO4yYwVUBVnuqQim5R7NoiAtKqLRLht_BjOTttysgUK7nEUs6--872fUfIuZYmiqCeg75OO0yHwhFSSMdTZhuGoQOjJt_56Zl3--x-4A9WyNUiF6bghygX3MzMsPbaTHCzIN1YsoYOZ8mF1zJ026sMYbk5z0dZb2GGEVfb6poYpCOE5K63YJ51aWPx5h-v8xeZWtfS2SQbc0wI7UKJW2RFZduk1itIpfM6RMscqWkdatBb0k3nO-Tn5TUHhHEwSST6IUiLYhw5JNkQlDX7OMgyKPNv1RQy9FkwG0H6MT8-DuOykBeM559_Q1HT5SVEI7DVJeqgvsbvSYqNIukt_VZ1MOJoGUzTdJmWKV54a5f0O7fRddeZ11xwJGt53JEhV54rRRKwUGkhQya157pSS61stMESgygTXzRpUyiX6iBBgC5lKHwuUHaPVLJRpg4INFuBkL4vBB2iDlwZBJq7GgEQQj42pLxK9ou_H48LYo3YC3jg85BWSc2qo3xQcCvTGBUXG8XFN1HbXA__K3hG1rrR02P8ePf8cETWqSnia49eH5PKbPKpThBZzMSpHUG_y4bNIw |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1LT8MwDI4QSIgL4v0GH9BOK3RpmrXcEDDx1g5DcKuaNBEV0FUwJMZv4cdip13HkVOj1m2kOrE_J_Fnxg6tpiiCBx76OusJGytPaaW9wNA2jEAHxinf-e5eXj6I66fwqT5VSbkwFT9Es-BGM8PZa5rgZWaPp6Sh2Sg9CrrEtj1He300KbnoT6wwwmpXXBNjdESQ0g8mxLM-P568-cfp_AWmzrP0lthiDQnhtNLhMpsxxQpr9StO6XEbBtMUqY82tKA_ZZser7Kfx-cxIIqD91SjG4K8qsUxhrTIwDirj2OsgCb91nxAgS4LRkPI3-rT41A2dbygrD__gqLU5QkMhuCKS7TBfJWvaY6NKuct_zZtIHE0DNSkLvMmwwtvrbGH3sXg7NKrSy54WnQD6elYmsDXKo1EbKzSsdA28H1ttTUu2BApAco0VB3eUcbnNkoRn2sdq1AqlF1ns8WwMJsMOt1I6TBUimeoA19HkZW-RfyDiE9kXG6xjervJ2XFq5EEkYxCGfMt1nLqaB5U1Mo8QcUlpLjkfHBK1-3_Ch6w-f55L7m9ur_ZYQucSvi6g9e7bHb0_mn2EFeM1L4bQL-3ocxM |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Why+the+racing+industry+and+equestrian+disciplines+need+to+implement+population+pharmacokinetics%3A+To+learn%2C+explain%2C+summarize%2C+harmonize%2C+and+individualize&rft.jtitle=Drug+testing+and+analysis&rft.au=Toutain%2C+Pierre%E2%80%90Louis&rft.date=2025-02-01&rft.issn=1942-7603&rft.eissn=1942-7611&rft.volume=17&rft.issue=2&rft.spage=250&rft.epage=258&rft_id=info:doi/10.1002%2Fdta.3706&rft.externalDBID=10.1002%252Fdta.3706&rft.externalDocID=DTA3706 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1942-7603&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1942-7603&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1942-7603&client=summon |